- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04563949
DermTech's Non-Invasive Pigmented Lesion Assay to Detect and Track Lesions for Suspected Melanoma and to Determine Outcomes for up to 2 Years (TRUST)
Clinical Practice Utility Study to Assess DermTech's Non-Invasive Pigmented Lesion Assay to Detect and Track Lesions for Suspected Melanoma and to Determine Outcomes for up to 2 Years
Study Overview
Detailed Description
This is a multi-center, sample collection study to follow clinically suspicious lesions to determine the outcome including surgical biopsy, removal, monitoring, etc. for up to 2 years after lesion identification.
Subjects will be consented and enter the trial to have their suspicious lesion(s), biopsied via DermTech's adhesive patch biopsy and assessed with DermTech's non-invasive PLA, and followed up to 2 years per standard of care. Lesions must be photographed and/or the site of the lesion anatomically defined to permit follow-up of the lesion(s) and lesional site(s) during future visits.
Subjects will be followed per standard of care for lesion biopsy, excision, treatment and/or monitoring. Other than DermTech's non-invasive PLA of the lesion(s) no other study procedures will be performed and subjects will be treated according to the standard of care. The subject's medical management team should use standard of care, visual assessment changes (i.e., "ABCDE") and physician judgment for suspicious lesion characterization and monitoring when planning the subject's course of treatment.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92121
- West Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Males and females the treating physician chose to use the PLA on;
- Presence of a lesion(s) that is suspicious for melanoma and a candidate for surgical biopsy that was previously biopsied with DermTech's adhesive patch biopsy and assessed via PLA;
- Willing to permit subsequent PLA assays to be performed on suspicious lesions;
- Willing to follow standard of care treatment for the lesion(s) as determined by the treating physician;
- Subjects must be able to complete study visits required by the protocol (subject is not planning to relocate or travel thus prevent attendance at future study visits; and
- Willing to provide informed consent to participate in this trial.
Exclusion Criteria:
- Has confirmed melanoma or a suspicious lesion that required a surgical biopsy or excision prior to the intial PLA on that lesion of interest;
- Has an ulcerated or bleeding lesion that could cofound the PLA results;
- Has a suspicious lesion(s) in an area that was previously surgically biopsied;
- The lesion(s) is on the palms, mucosal surface, or other area where adhesive patch biopsies cannot be performed;
- Has an allergy to tape or latex rubber;
- Receipt of any investigational drug therapy within four weeks of study enrollment, or concurrent participation in another interventional clinical study deemed by the treating physician to potentially influence this study; and
- Documented substance abuse, any other significant medical condition or laboratory result that would indicate an unreasonable risk to the subject or potential interference with study procedures, or would negatively affect the patient's reliability and compliance with the study schedule of events. -
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
PLA-
PLA- initially and repeat testing 1-2 years later
|
Repeat Testing with the PLA will be conducted
|
PLA+
Not eligible for the study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects without surgical biopsy
Time Frame: approximately up to 24 months
|
The proportion of subjects who exit the study without surgical biopsy out to approximately up to 24 months ± SOC
|
approximately up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Results of PLA results compared to biopsy
Time Frame: approximately up to 24 months
|
Expression of genes during the 2-year study.
The association of gene expression and algorithm values with melanoma versus non-melanoma will be examined using clinical performance indicators negative predictive value with their respective 95th percentile confidence intervals.
|
approximately up to 24 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Ferris LK, Jansen B, Ho J, Busam KJ, Gross K, Hansen DD, Alsobrook JP 2nd, Yao Z, Peck GL, Gerami P. Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy. JAMA Dermatol. 2017 Jul 1;153(7):675-680. doi: 10.1001/jamadermatol.2017.0473.
- Gerami P, Yao Z, Polsky D, Jansen B, Busam K, Ho J, Martini M, Ferris LK. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol. 2017 Jan;76(1):114-120.e2. doi: 10.1016/j.jaad.2016.07.038. Epub 2016 Oct 1.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma Detection
-
Taipei Veterans General Hospital, TaiwanRecruiting
-
Harvard Pilgrim Health CareDuke University; Brigham and Women's Hospital; University of California, San... and other collaboratorsActive, not recruiting
-
Quanovate Tech Inc.Recruiting
-
Western Norway University of Applied SciencesThe Norwegian School of Sport Sciences; The Norwegian Doping Control LaboratoryNot yet recruitingPerformance, Detection | Doping
-
Thrive Earlier Detection CorpCompletedEarly Cancer DetectionUnited States
-
CareTaker Medical LLCCompletedRespiration Rate Detection
-
Women's College HospitalOttawa Hospital Research Institute; Cancer Care Ontario; Laval University; Ontario...CompletedClinical Trial | Early Detection of CancerCanada
-
ClinLogic LLCMDGlobalRecruitingEarly Detection of CancerUnited States
-
Andaluz Health ServiceCompletedEarly Detection of CancerSpain
Clinical Trials on Repeat Testing
-
University of California, San FranciscoEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPrimary Prevention of HIV AcquisitionUganda
-
Liverpool Heart and Chest Hospital NHS Foundation...Biosense Webster, Inc.CompletedAtrial FibrillationUnited Kingdom
-
Respivert LtdCompletedChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
Respivert LtdCompletedHealthy Volunteers | Chronic Obstructive Pulmonary Disease (COPD)United Kingdom
-
Respivert LtdTerminatedAsthma | Healthy VolunteersUnited Kingdom
-
University Medical Center GroningenCompleted
-
Respivert LtdCompletedAsthma | Healthy VolunteersUnited Kingdom
-
Karolinska InstitutetUniversité Catholique de LouvainRecruitingLupus NephritisSweden
-
University Medical Center GroningenCompletedThoracic TumorNetherlands
-
University of PittsburghUnited States Department of DefenseCompletedFacial Injuries | Adipose TissueUnited States